Category : Search result: pharmaceutical fines


Novo Nordisk Alzheimer's Drug Trials Fail

Danish pharmaceutical giant Novo Nordisk faces major setback as Alzheimer's drug trials fail. Learn how this impacts the weight-loss leader's expansion plans.

Eli Lilly Reaches $1 Trillion Valuation Milestone

Eli Lilly becomes the first pharmaceutical company to achieve a US$1 trillion market valuation, driven by unprecedented demand for its weight-loss treatments. Discover how this milestone reshapes the industry.

Denmark compensates for Novo Nordisk vision loss

Danish authorities provide compensation to patients experiencing vision loss linked to Novo Nordisk medications. Learn about the pharmaceutical safety developments affecting Canadian consumers.

J&J buys Halda Therapeutics for $3.05 billion

Johnson & Johnson expands its oncology portfolio with $3.05 billion acquisition of Halda Therapeutics, strengthening its cancer treatment pipeline. Learn about this major healthcare investment.

Barbados Launches US$200M Life Sciences Hub

Barbados partners with EarlyHealth Group to build a US$200 million life sciences hub, positioning the island as the Caribbean's premier pharmaceutical and research centre.

Pfizer wins $10B obesity drug takeover battle

Pfizer triumphs in dramatic $10 billion bidding war for obesity drug maker Metsera, securing crucial White House-backed deal to compete in weight-loss market. Read the full story.

Trump's Plan to Slash Obesity Drug Prices

Former President Donald Trump unveils ambitious strategy to dramatically reduce costs of groundbreaking weight-loss medications, promising relief for millions struggling with obesity.

Nova Scotia MP fined for election violations

Liberal MP Jaime Battiste faces $600 penalty for violating Canada Elections Act during 2019 campaign through improper expense reporting and acceptance of prohibited contributions.

Trump's Drug Price Plan Backfires, Helps Democrats

Former President Trump's proposal to regulate Medicare drug prices faces unexpected consequences as Democrats leverage it to attack Republican positions on healthcare, creating political turmoil.

Trump Obesity Drug Deal Boosts Pharma Stocks

Major pharmaceutical giants Novo Nordisk and Eli Lilly experience significant stock surges as former President Donald Trump considers a groundbreaking obesity drug partnership, potentially revolutionizing weight loss treatment accessibility.

Page 2 of 3